胰高血糖素
胰高血糖素受体
医学
糖尿病
内分泌学
胰高血糖素样肽1受体
内科学
低血糖
肠促胰岛素
2型糖尿病
受体
兴奋剂
2型糖尿病
胰岛素
标识
DOI:10.3760/cma.j.issn.1673-4157.2018.01.004
摘要
Among these diabetic drugs based on glucagon, endogenous glucagon can rapidly increase blood glucose and is used as a first aid for severe hypoglycemia in clinic; the development of glucagon receptor antagonists is due to the hyperglucagon secretion in diabetic patients, anti-glucagon can lower blood glucose in diabetic patients; moreover, in addition to hyperglycemic effect, glucagon can also reduce blood lipid and promote energy consumption, which provides a theoretical basis for the research and development of glucagon receptor agonists, its dual receptor agonists with incretin can further benefit obese diabetic patients. Although most of these drugs are still in preclinical studies, they are expected to be effective drugs controlling blood glucose in the treatment of diabetes mellitus and bring hopes to patients with diabetes mellitus.
Key words:
Glucagon; Glucagon receptor antagonists; Glucagon receptor agonists
科研通智能强力驱动
Strongly Powered by AbleSci AI